data:image/svg+xml;base64,PHN2ZyB4bWxucz0iaHR0cDovL3d3dy53My5vcmcvMjAwMC9zdmciIHZpZXdCb3g9IjAgODUuMzMzIDUxMiAzNDEuMzMzIj48cGF0aCBmaWxsPSIjRDgwMDI3IiBkPSJNMCA4NS4zMzFoNTEydjM0MS4zMzdIMHoiLz48cGF0aCBkPSJNMCA4NS4zMzFoNTEydjExMy43NzVIMHoiLz48cGF0aCBmaWxsPSIjRkZEQTQ0IiBkPSJNMCAzMTIuODgyaDUxMnYxMTMuNzc1SDB6Ii8+PC9zdmc+

data:image/svg+xml;base64,PHN2ZyB4bWxucz0iaHR0cDovL3d3dy53My5vcmcvMjAwMC9zdmciIHZpZXdCb3g9IjAgODUuMzMzIDUxMiAzNDEuMzMzIj48cGF0aCBmaWxsPSIjRkZEQTQ0IiBkPSJNMCA4NS4zMzFoNTEydjM0MS4zMzdIMHoiLz48cGF0aCBkPSJNMCA4NS4zMzFoNTEydjExMy43NzVIMHptMCAyMjcuNTUxaDUxMnYxMTMuNzc1SDB6IiBmaWxsPSIjRDgwMDI3Ii8+PC9zdmc+

data:image/svg+xml;base64,PHN2ZyB4bWxucz0iaHR0cDovL3d3dy53My5vcmcvMjAwMC9zdmciIHZpZXdCb3g9IjAgODUuMzMzIDUxMiAzNDEuMzMzIj48cGF0aCBmaWxsPSIjRkZGIiBkPSJNMCA4NS4zMzdoNTEydjM0MS4zMjZIMHoiLz48cGF0aCBmaWxsPSIjRkY5ODExIiBkPSJNMCA4NS4zMzdoNTEydjExMy43NzVIMHoiLz48cGF0aCBmaWxsPSIjNkRBNTQ0IiBkPSJNMCAzMTIuODg4aDUxMnYxMTMuNzc1SDB6Ii8+PGNpcmNsZSBmaWxsPSIjMDA1MkI0IiBjeD0iMjU2IiBjeT0iMjU2IiByPSI0My44OTYiLz48Y2lyY2xlIGZpbGw9IiNGRkYiIGN4PSIyNTYiIGN5PSIyNTYiIHI9IjI3LjQzNCIvPjxwYXRoIGZpbGw9IiMwMDUyQjQiIGQ9Ik0yNTYgMjIyLjE0Nmw4LjQ2NCAxOS4xOTUgMjAuODU1LTIuMjY4TDI3Mi45MjcgMjU2bDEyLjM5MiAxNi45MjctMjAuODU1LTIuMjY4TDI1NiAyODkuODU0bC04LjQ2NC0xOS4xOTUtMjAuODU1IDIuMjY4TDIzOS4wNzMgMjU2bC0xMi4zOTItMTYuOTI3IDIwLjg1NSAyLjI2OHoiLz48L3N2Zz4=

data:image/svg+xml;base64,PHN2ZyB4bWxucz0iaHR0cDovL3d3dy53My5vcmcvMjAwMC9zdmciIHZpZXdCb3g9IjAgODUuMzMzIDUxMiAzNDEuMzMzIj48cGF0aCBmaWxsPSIjRkZGIiBkPSJNMzQxLjMzNCA4NS4zM0gwdjM0MS4zMzJoNTEyVjg1LjMzeiIvPjxwYXRoIGZpbGw9IiM2REE1NDQiIGQ9Ik0wIDg1LjMzM2gxNzAuNjYzVjQyNi42N0gweiIvPjxwYXRoIGZpbGw9IiNEODAwMjciIGQ9Ik0zNDEuMzM3IDg1LjMzM0g1MTJWNDI2LjY3SDM0MS4zMzd6Ii8+PC9zdmc+

data:image/svg+xml;base64,PHN2ZyB4bWxucz0iaHR0cDovL3d3dy53My5vcmcvMjAwMC9zdmciIHZpZXdCb3g9IjAgODUuMzMzIDUxMiAzNDEuMzMzIj48cGF0aCBmaWxsPSIjRkZGIiBkPSJNMCA4NS4zMzFoNTEydjM0MS4zMzdIMHoiLz48cGF0aCBmaWxsPSIjMDA1MkI0IiBkPSJNMCA4NS4zMzFoMTcwLjY2M3YzNDEuMzM3SDB6Ii8+PHBhdGggZmlsbD0iI0Q4MDAyNyIgZD0iTTM0MS4zMzcgODUuMzMxSDUxMnYzNDEuMzM3SDM0MS4zMzd6Ii8+PC9zdmc+

+ New Watchlist

Benzinga Research

-

-

-

-

-

-

-

Get Benzinga Pro
Data & APIs
Events
Marketfy
Premarket
Boost
Advertise

data:image/svg+xml;base64,PHN2ZyB4bWxucz0iaHR0cDovL3d3dy53My5vcmcvMjAwMC9zdmciIHZpZXdCb3g9IjAgODUuMzMzIDUxMiAzNDEuMzMzIj48cGF0aCBmaWxsPSIjRDgwMDI3IiBkPSJNMCA4NS4zMzFoNTEydjM0MS4zMzdIMHoiLz48cGF0aCBkPSJNMCA4NS4zMzFoNTEydjExMy43NzVIMHoiLz48cGF0aCBmaWxsPSIjRkZEQTQ0IiBkPSJNMCAzMTIuODgyaDUxMnYxMTMuNzc1SDB6Ii8+PC9zdmc+

data:image/svg+xml;base64,PHN2ZyB4bWxucz0iaHR0cDovL3d3dy53My5vcmcvMjAwMC9zdmciIHZpZXdCb3g9IjAgODUuMzMzIDUxMiAzNDEuMzMzIj48cGF0aCBmaWxsPSIjRkZEQTQ0IiBkPSJNMCA4NS4zMzFoNTEydjM0MS4zMzdIMHoiLz48cGF0aCBkPSJNMCA4NS4zMzFoNTEydjExMy43NzVIMHptMCAyMjcuNTUxaDUxMnYxMTMuNzc1SDB6IiBmaWxsPSIjRDgwMDI3Ii8+PC9zdmc+

data:image/svg+xml;base64,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

data:image/svg+xml;base64,PHN2ZyB4bWxucz0iaHR0cDovL3d3dy53My5vcmcvMjAwMC9zdmciIHZpZXdCb3g9IjAgODUuMzMzIDUxMiAzNDEuMzMzIj48cGF0aCBmaWxsPSIjRkZGIiBkPSJNMzQxLjMzNCA4NS4zM0gwdjM0MS4zMzJoNTEyVjg1LjMzeiIvPjxwYXRoIGZpbGw9IiM2REE1NDQiIGQ9Ik0wIDg1LjMzM2gxNzAuNjYzVjQyNi42N0gweiIvPjxwYXRoIGZpbGw9IiNEODAwMjciIGQ9Ik0zNDEuMzM3IDg1LjMzM0g1MTJWNDI2LjY3SDM0MS4zMzd6Ii8+PC9zdmc+

data:image/svg+xml;base64,PHN2ZyB4bWxucz0iaHR0cDovL3d3dy53My5vcmcvMjAwMC9zdmciIHZpZXdCb3g9IjAgODUuMzMzIDUxMiAzNDEuMzMzIj48cGF0aCBmaWxsPSIjRkZGIiBkPSJNMCA4NS4zMzFoNTEydjM0MS4zMzdIMHoiLz48cGF0aCBmaWxsPSIjMDA1MkI0IiBkPSJNMCA4NS4zMzFoMTcwLjY2M3YzNDEuMzM3SDB6Ii8+PHBhdGggZmlsbD0iI0Q4MDAyNyIgZD0iTTM0MS4zMzcgODUuMzMxSDUxMnYzNDEuMzM3SDM0MS4zMzd6Ii8+PC9zdmc+

Our Services
News
Earnings
Guidance
Dividends
M&A
Buybacks
Legal
Interviews
Management
Offerings
IPOs
Insider Trades
Biotech/FDA
Politics
Government
Healthcare
Markets
Pre-Market
After Hours
Movers
ETFs
Forex
Cannabis
Commodities
Options
Binary Options
Bonds
Futures
CME Group
Global Economics
Previews
Small-Cap
Real Estate
Cryptocurrency
Penny Stocks
Digital Securities
Volatility
Ratings
Analyst Color
Downgrades
Upgrades
Initiations
Price Target
Ideas
Trade Ideas
Covey Trade Ideas
Long Ideas
Short Ideas
Technicals
From The Press
Jim Cramer
Rumors
Best Stocks & ETFs
Best Penny Stocks
Best S&P 500 ETFs
Best Swing Trade Stocks
Best Blue Chip Stocks
Best High-Volume Penny Stocks
Best Small Cap ETFs
Best Stocks to Day Trade
Best REITs
Money
Investing
Cryptocurrency
Mortgage
Insurance
Yield
Personal Finance
Forex
Startup Investing
Real Estate Investing
Credit Cards
Crypto
Cannabis
Cannabis Conference
News
Earnings
Interviews
Deals
Regulations
Psychedelics
Jobs

Free Benzinga Pro Trial

Calendars

Analyst Ratings Calendar

Conference Call Calendar

Dividend Calendar

Earnings Calendar

Economic Calendar

Guidance Calendar

Stock Split Calendar

Trade Ideas

Free Stock Reports

Trade Idea Feed

Analyst Ratings

Unusual Options Activity

Free Newsletter

Government Trades

Short Interest

Largest Increase

Largest Decrease

Calculators

Margin Calculator

Forex Profit Calculator

100x Options Profit Calculator

-

-

-

-

-

-

-

Lexaria Bioscience

(NASDAQ:LEXXW)

Intraday

$0.5111

-0.2489[-32.75%]

After-Hours

$2.40

1.8889[369.58%]

Perks Buy Compare Brokers

$0.5111

-0.2489[-32.75%]

At close: Apr 24

$2.40

1.8889[369.58%]

After Hours: 5:30PM EDT

Overview News Earnings Guidance Dividends Analyst Ratings Insider Trades Short Interest

Latest News for Lexaria Bioscience Stock (NASDAQ:LEXXW)

Lexaria Bioscience Stock (NASDAQ: LEXXW)

Categories: All

All News

General

Contracts

Dividends

Events

FDA

M&A

Offerings

Stock Split

Media

Buybacks

Insider Trades

Earnings

Guidance

Analyst Ratings

Trading Ideas

All News

General

Contracts

Dividends

Events

FDA

M&A

Offerings

Stock Split

Media

Buybacks

Insider Trades

Earnings

Guidance

Analyst Ratings

Trading Ideas

Tuesday, April 16, 2024

Lexaria Receives Ethics Review Board Approval To Begin New GLP-1 Study, Investigating GLP-1 Drugs And DehydraTECH
Benzinga Newsdesk - Apr 16, 2024, 9:17AM

Thursday, March 14, 2024

Lexaria Appoints Nelson Cabatuan As Chief Financial Officer, Effective Immediately
Benzinga Newsdesk - Mar 14, 2024, 9:22AM

Tuesday, March 05, 2024

Lexaria To Begin Diabetes And Weight Loss Animal Study WEIGHT-A24-1
Benzinga Newsdesk - Mar 5, 2024, 9:10AM

Thursday, December 07, 2023

Lexaria Bioscience Corp. Announces That The Co's Anticipated Submission Of An Investigational New Drug Application With The U.S. FDA For Its Planned U.S. Phase 1b Hypertension Clinical Trial Is Expected To Be Filed Within ~45 Days
Benzinga Newsdesk - Dec 7, 2023, 9:22AM

Friday, October 13, 2023

Lexaria Enters New Global Exclusive Collaboration And License Agreement With SulfoSyn; Global Exclusivity For All Non-Pharmaceutical Applications Of DehydraTECH-Sulforaphane Has Been Awarded
Happy Mohamed - Oct 13, 2023, 9:07AM

Thursday, September 21, 2023

Lexaria To Evaluate Impact Of DehydraTECH On Oral Performance Of GLP-1 Drugs Used In Products Such As Ozempic, Wegovy And Rybelsus, Alone Or Together With DehydraTECH-CBD
Benzinga Newsdesk - Sep 21, 2023, 9:16AM

Wednesday, August 30, 2023

Lexaria Provides Update On Investigational New Drug Application Progress With The FDA For Its Planned U.S. Phase 1b Hypertension Clinical Trial Designated As HYPER-H23-1
Happy Mohamed - Aug 30, 2023, 9:24AM

Wednesday, August 02, 2023

Lexaria's Plans To Study Weight Loss And Diabetes Control In A Human Clinical Study With DehydraTECH-CBD
Happy Mohamed - Aug 2, 2023, 9:14AM

Friday, July 28, 2023

Lexaria Incorporates New Subsidiary For CPG Products And Updates Human Nicotine Study
Happy Mohamed - Jul 28, 2023, 9:11AM

Wednesday, July 19, 2023

Lexaria Granted Strategically Important New U.S. Patent For DehydraTECH-Nicotine Including Oral Pouch Products
Happy Mohamed - Jul 19, 2023, 9:06AM

Friday, June 16, 2023

Lexaria's DehydraTECH-CBD Lowers Blood Glucose Levels In Diabetes Animal Study
Benzinga Newsdesk - Jun 16, 2023, 9:11AM

Tuesday, May 23, 2023

Lexaria's Formulated Cannabidiol Showed Reduction In Pro-Inflammatory Biomarkers Associated with Heart Diseases
Vandana Singh - May 23, 2023, 2:41PM

Thursday, May 18, 2023

Lexaria's Hormone Study Shows Significant Enhancement In Oral Estradiol Delivery
Happy Mohamed - May 18, 2023, 9:08AM

Monday, April 24, 2023

Lexaria Awards CRO Contract For Upcoming U.S. Phase 1b Hypertension Study
Happy Mohamed - Apr 24, 2023, 9:05AM

Thursday, March 02, 2023

Lexaria's DehydraTECH-CBD Diabetes Study Demonstrates Weight Loss, Improved Triglyceride And Cholesterol Levels
Vuk Zdinjak - Mar 2, 2023, 11:13AM

Monday, January 23, 2023

Former President Of GW Pharmaceuticals USA Joins Lexaria Bioscience As Strategic Advisor
Benzinga Newsdesk - Jan 23, 2023, 8:50AM

Wednesday, December 21, 2022

Lexaria's DehydraTECH-CBD Achieves Superior Human Blood Absorption Levels
Benzinga Newsdesk - Dec 21, 2022, 9:12AM

Tuesday, December 20, 2022

Lexaria's Human Oral Nicotine Study Begins Dosing
Benzinga Newsdesk - Dec 20, 2022, 12:37PM

Tuesday, November 08, 2022

Lexaria Starts Study Evaluating The Effect Of DehydraTECH-CBD On Diabetes
Benzinga Newsdesk - Nov 8, 2022, 9:14AM

Thursday, October 27, 2022

Lexaria's Human Clinical HYPER-H21-4 Study
Benzinga Newsdesk - Oct 27, 2022, 9:18AM

Wednesday, July 27, 2022

Lexaria's DehydraTECH CBD Hypertension Study Dosing Complete With No Serious Adverse Events
Vuk Zdinjak - Jul 27, 2022, 11:31AM

Tuesday, July 26, 2022

Lexaria's Licensee Premier Wellness Science Co., Ltd. Launches New Brand In Preparation To Deploy DehydraTECH CBD Products In Japan
Benzinga Newsdesk - Jul 26, 2022, 9:08AM

Tuesday, June 21, 2022

Lexaria Signs Manufacturing And License Agreements With BevNology
Bill Haddad - Jun 21, 2022, 9:11AM

Wednesday, June 08, 2022

Lexaria Grants License To AnodGen Bioceuticals
Bill Haddad - Jun 8, 2022, 9:05AM

Monday, June 06, 2022

Lexaria Files Pre-IND Meeting Request Letter With FDA
Benzinga Newsdesk - Jun 6, 2022, 9:18AM

Friday, April 22, 2022

Lexaria Bioscience (NASDAQ: LEXX) Secures Patent For DehydraTECH To Deliver Antivirals
InvestorBrandNetwork - Sponsored

Wednesday, April 20, 2022

Lexaria Bioscience (NASDAQ: LEXX) Commences Its Most Comprehensive Study To Date
InvestorBrandNetwork - Sponsored

Tuesday, April 19, 2022

Lexaria Commences Multi-Week Human Clinical Hypertension Study
Benzinga Newsdesk - Apr 19, 2022, 9:07AM

Wednesday, April 13, 2022

Lexaria Bioscience (NASDAQ: LEXX) Issues Update On Human Nicotine Study
InvestorBrandNetwork - Sponsored

Wednesday, March 16, 2022

Lexaria Bioscience Commences DehydraTECH-CBD Epilepsy Research Program
InvestorBrandNetwork - Sponsored

Tuesday, March 15, 2022

Lexaria Bioscience Reports First Phase Of Its Epilepsy Research Program Begun This Week; DehydraTECH-CBD Test Articles Have Been Manufactured, Delivered To Third-Party Lab Engaged To Complete Research
Benzinga Newsdesk - Mar 15, 2022, 2:12PM

Tuesday, March 08, 2022

Lexaria Granted Important New Oral Nicotine Patent
Benzinga Newsdesk - Mar 8, 2022, 9:16AM

Wednesday, February 02, 2022

Lexaria Highlights Findings In Sildenafil Animal Study
Benzinga Newsdesk - Feb 2, 2022, 9:30AM

Wednesday, December 08, 2021

From Benzinga's Global Small Cap Conference: Lexaria Bioscience, Head Of IR, George Jurcic Begins Presenting
Benzinga Newsdesk - Dec 8, 2021, 9:27AM
Lexaria Issues Follow-U Results From Clinical Study Showing DehydraTECHTM-CBD Reduces Arterial Stiffness
Bill Haddad - Dec 8, 2021, 7:32AM

Wednesday, November 10, 2021

Lexaria 2022 R&D Programs To Include Investigations Into Alzheimer's Disease And Diabetes
Benzinga Newsdesk - Nov 10, 2021, 9:03AM

Wednesday, November 03, 2021

Lexaria Shares Move Higher; Co Announces New Hypertension Study HYPER-H21-4
Benzinga Newsdesk - Nov 3, 2021, 7:56AM

Monday, November 01, 2021

Lexaria Bioscience Reports R&D Program To Compare Prescription Cannabidiol
Benzinga Newsdesk - Nov 1, 2021, 9:02AM

Wednesday, October 13, 2021

Lexaria Bioscience Reports Recent Oral THC Absorption Study Revealed Its DehydraTECH Required 15 Mins. To Deliver THC Levels In Blood Plasma
Benzinga Newsdesk - Oct 13, 2021, 11:03AM

Wednesday, September 08, 2021

Lexaria Begins Investigational New Drug Enabling Program For DehydraTECH-CBD For Hypertension
Benzinga Newsdesk - Sep 8, 2021, 7:19AM

Tuesday, September 07, 2021

Lexaria Bioscience Announces Initial Results From Human Clinical Study Of DehydraTECHTM; Study Evidences Up To 23% Decrease In Blood Pressure With DehydraTECH-CBD Relative to Placebo
Bill Haddad - Sep 7, 2021, 7:13AM

Thursday, July 29, 2021

Lexaria Highlights Results From Human Clinical Study Of HYPER-H21-1
Bill Haddad - Jul 29, 2021, 7:16AM
Lexaria's DehydraTECH-CBD Lowers Blood Pressure
The Newswire - Jul 29, 2021, 7:05AM

Wednesday, July 28, 2021

Lexaria Bioscience Earlier Announced Its DehydraTECH Technology Is Now Available For Sale In 7K+ Stores Across The US
Benzinga Newsdesk - Jul 28, 2021, 7:10AM
DehydraTECH(TM) - Enabled Consumer Products Now Available in Over 7,000 Stores
The Newswire - Jul 28, 2021, 7:05AM

Tuesday, July 27, 2021

Lexaria Completes Dosing in Human Clinical Study HYPER-H21-2
The Newswire - Jul 27, 2021, 7:15AM

Monday, July 26, 2021

Lexaria Receives US$3,817,643 From Warrant Exercises
The Newswire - Jul 26, 2021, 2:40PM

Thursday, July 22, 2021

Lexaria Summarizes Successful Antiviral Drug Studies and Ongoing Strategy
The Newswire - Jul 22, 2021, 7:05AM

Wednesday, July 21, 2021

Lexaria Highlights VIRAL-A20-3 STudy Results Showing 'Possible Benefits for Treating SARS-CoV-2/COVID-19 and mRNA Vaccine Side Effects'
Bill Haddad - Jul 21, 2021, 7:06AM
Lexaria's DehydraTECH Significantly Enhances Delivery of Colchicine in Study VIRAL-A20-3
The Newswire - Jul 21, 2021, 7:05AM

Create a Watchlist

FREE: Follow your stocks and cryptocurrencies with the most actionable alerts on the internet.

People Also Watch

Popular Channels

PreMarket Prep
Press Releases
Analyst Ratings
News
Options
ETFs

Tools & Features

Real Time Feed
Public RSS Feeds
Submit News Tips
Blog
Embeddable Finance Widgets & Tools
Benzinga Catalyst

Partners & Contributors

Affiliate Program
Contributor Portal
Licensing & Syndication
Sponsored Content
Advertise With Us
Lead Generation & SEO

About Benzinga

About Us
Careers
In The News
Events
Contact Us

Terms & Conditions
Do Not Sell My Personal Data/Privacy Policy
Disclaimer
Service Status
Sitemap

© 2024 Benzinga | All Rights Reserved